Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vincristine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vincristine SCHEMBL3999 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL13300978 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL233849 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL4322545 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL13662639 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL13840950 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL13321219 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL14177979 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL3709 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL4769981 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017735-B2 | Comprising one or more binding compositions comprising a member selected from a light chain amino acid sequence which comprises CDR-L1 and a heavy chain amino acid sequence which comprises CDR-H1 in association with one or more chemotherapeutic agents; cancer therapy | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |